Taipei, Taiwan, November 7, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader headquartered in Taiwan, announced its unaudited consolidated revenue for October 2024, totaling NT$1,885 million, presenting an impressive 59% month-over-month (MoM) growth and a 107% increase year-over-year (YoY). This concludes the company’s year-to-date revenue of NT$ 16,060 million, marking an 11% YoY growth.
In October, the company’s export revenue surged over 300% year-over-year, fueled by robust lenalidomide sales in the U.S. Asian revenues rose by 18% compared to the same period last year, supported by strong performances in Thailand and Korea. Thailand’s growth was driven by demand for the osteoporosis product Aclasta and respiratory product Inhalex Forte, while Korea's results were bolstered by the weight management product Qsymia and the birth control product Mercilon.
In 2024, several of Lotus's products demonstrated sustained growth. In addition to the key product Lenalidomide, the novel small cell lung cancer(SCLC)treatment Zepzelca® (lurbinectedin) showed a remarkable 200% YoY growth year-to-date. Lotus licensed Taiwan commercial right of Zepzelca from Spain based PharmaMar S.A in 2021 and launched in Taiwan in 2023. Currently Zepzelca is marketed for “the treatment of adult patients with metastatic SCLC whose disease has progressed during or after platinum-based chemotherapy." Depending on the dosage, the cost per treatment cycle ranges from NT$80,000 to NT$160,000. To date, approximately 220 SCLC patients in Taiwan have received Zepzelca treatment.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on delivering novel and generic medicines that are safer, better, and more accessible. With a best-in-class R&D and manufacturing platform in Asia, Lotus has partnerships in key markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in development and registration across Asia and the U.S., with a portfolio of more than 250 commercial products. Lotus invests in a diversified pipeline of high-barrier oncology treatments, complex generics, 505(b)2 products, and new chemical entities (NCEs), through internal R&D and licensing partnerships. Additionally, it bolsters its portfolio with biosimilars, supported by strategic alliances. Lotus's facilities are certified by top regulatory bodies, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com